What is he best known for?
The fields of study he is best known for:
His main research concerns Leukemia, Immunology, Antibody, Monoclonal antibody and Antigen.
His Leukemia research is multidisciplinary, incorporating perspectives in Acute promyelocytic leukemia and Bone marrow.
His Immunology research incorporates elements of Cancer and Cancer research.
The study incorporates disciplines such as Neoplasm, Molecular biology, Pharmacokinetics and Cell killing in addition to Antibody.
His Monoclonal antibody study combines topics from a wide range of disciplines, such as In vitro, Catabolism, Stereochemistry, Combinatorial chemistry and In vivo.
His work carried out in the field of Antigen brings together such families of science as Chronic myelogenous leukemia, Cytotoxic T cell and Peptide sequence.
His most cited work include:
- Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). (1169 citations)
- Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide (1093 citations)
- Central challenges facing the national clinical research enterprise. (992 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Cancer research, Immunology, Antibody, Monoclonal antibody and Leukemia.
His Cancer research study also includes
- Cytotoxic T cell together with T cell,
- Immunotherapy that intertwine with fields like Tumor microenvironment.
His Immunology study which covers Internal medicine that intersects with Endocrinology.
His Antibody research is multidisciplinary, incorporating elements of In vitro, Antigen, Receptor, Molecular biology and T-cell receptor.
His studies deal with areas such as Epitope, In vivo and Virology as well as Monoclonal antibody.
David A. Scheinberg interconnects Myeloid, Chemotherapy, Bone marrow and Acute promyelocytic leukemia in the investigation of issues within Leukemia.
He most often published in these fields:
- Cancer research (33.13%)
- Immunology (26.38%)
- Antibody (25.77%)
What were the highlights of his more recent work (between 2013-2021)?
- Cancer research (33.13%)
- T-cell receptor (15.54%)
- Antibody (25.77%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Cancer research, T-cell receptor, Antibody, Antigen and Epitope.
His Cancer research research integrates issues from Chimeric antigen receptor, Immune system, Immunotherapy, Human leukocyte antigen and Antigen presentation.
David A. Scheinberg focuses mostly in the field of Antibody, narrowing it down to matters related to Biodistribution and, in some cases, DOTA.
His Antigen study improves the overall literature in Immunology.
He works on Immunology which deals in particular with Leukemia.
His Monoclonal antibody course of study focuses on Molecular biology and CD8.
Between 2013 and 2021, his most popular works were:
- Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (279 citations)
- Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (279 citations)
- Acute myeloid leukaemia. (262 citations)
In his most recent research, the most cited papers focused on:
His primary areas of investigation include Cancer research, Antigen, Molecular biology, CD8 and T-cell receptor.
The Cancer research study combines topics in areas such as Cell, Cancer cell, MHC class I, Major histocompatibility complex and Epitope.
The subject of his Antigen research is within the realm of Immunology.
His studies deal with areas such as Antibody, Monoclonal antibody and Human leukocyte antigen as well as Molecular biology.
His T-cell receptor study incorporates themes from Leukemia, Stem cell and Intracellular.
His Leukemia research includes themes of Myeloid and Wilms' tumor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
